CO

Envoy Medical, Inc.

COCHHealthcareNASDAQ

Medical Devices · Last scanned Jul 22, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$241,000
+7.1% YoY
Net Income
-$23.8M
-14.2% YoY
EBITDA
-$21.9M
-10.4% YoY
Free Cash Flow
-$7.9M

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 15 MACD Positive CrossoverHistogram +0.0009, positive momentum
Jul 14 MACD Negative CrossoverHistogram -0.0021, negative momentum
About Envoy Medical, Inc.

Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The $52.4M market capitalization puts COCH squarely in micro-cap range for its industry. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire.

Where COCH stands vs its 150-day and 200-day moving averages

As of the July 15, 2026 close, COCH finished 10.14% above its 150-day moving average ($0.69) and 5.56% above its 200-day moving average ($0.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is COCH overbought or oversold?

At the July 15, 2026 close, COCH's RSI(14) was 61.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$52.4M
Fwd P/E-3.58
EPS$-1.04
Beta1.86
52W Change-57.7%
Analysis

Envoy Medical, Inc. holds $25.3M in cash against $889K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$7.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been relatively flat, moving from $237K (2022) to $241K (2025).

Envoy Medical, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, COCH has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Envoy Medical, Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
COCH: Envoy Medical, Inc. Technical Analysis (200-Day MA, RSI, MACD) | Scanance